ANDREWS RONALD ASBURY — SEC insider filings
SEC reporting owner CIK 1299153. 31 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2021-03-01 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 101,000 shares, $155,252 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 66.
- Largest priced transaction: purchase of 50,000 shares @ $1.28 ($64,150) in Oncocyte Corp, filed 2022-03-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Oncocyte Corp (OCX) | Former CEO, Director | 8 | 3 legs · 101,000 sh · $155,252 | — | 24 |
| Precipio, Inc. (PRPO) | Director | 18 | — | — | 26 |
| CERENOME, INC. (CNSY) | Chief Business Officer, Director | 4 | — | — | 8 |
| Oxford Immunotec Global PLC (OXFD) | Director | 1 | — | — | 8 |
Insider filings — ANDREWS RONALD ASBURY
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | CERENOME, INC. (CNSY) | Grant/award (A): 92,858 (derivative) @ $0 | EDGAR |
| 2026-10-01 | 4 | CERENOME, INC. (CNSY) | Option exercise (M): 921 @ $0 · Option exercise (M): 921 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | PLUS THERAPEUTICS, INC. (PSTV) | Option exercise (M): 922 @ $0 · Option exercise (M): 922 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | PLUS THERAPEUTICS, INC. (PSTV) | Grant/award (A): 3,686 (derivative) @ $0 · Grant/award (A): 3,686 (derivative) @ $0 · Grant/award (A): 1,600 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4/A | Precipio, Inc. (PRPO) | Grant/award (A): 568 @ $17.58 | EDGAR |
| 2026-01-06 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 568 @ $17.58 | EDGAR |
| 2025-07-18 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 676 @ $14.78 | EDGAR |
| 2025-04-17 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,785 @ $5.60 | EDGAR |
| 2025-01-16 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,639 @ $6.10 | EDGAR |
| 2025-01-16 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-10-17 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,510 @ $6.62 | EDGAR |
| 2024-09-06 | 4 | Precipio, Inc. (PRPO) | Disposition to issuer (D): 103 (derivative) @ $0 · Grant/award (A): 103 (derivative) @ $0 · Disposition to issuer (D): 258 (derivative) @ $0 · Grant/award (A): 258 (derivative) @ $0 · Disposition to issuer (D): 1,250 (derivative) @ $0 · Grant/award (A): 1,250 (derivative) @ $0 · +2 more | EDGAR |
| 2024-07-16 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 2,157 @ $4.63 | EDGAR |
| 2024-06-25 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 1,000 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 3,153 @ $6.66 | EDGAR |
| 2023-10-26 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 4,005 | EDGAR |
| 2023-09-14 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 6,060 | EDGAR |
| 2023-01-10 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 30,000 (derivative) | EDGAR |
| 2022-12-09 | 4 | Oncocyte Corp (OCX) | Option exercise (M): 250,000 @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 45,000 (derivative) @ $0 · Disposition to issuer (D): 950,000 (derivative) @ $0 · Disposition to issuer (D): 50,000 (derivative) @ $0 · Disposition to issuer (D): 500,000 (derivative) @ $0 · +6 more | EDGAR |
| 2022-08-18 | 4 | Oncocyte Corp (OCX) | Purchase (P): 40,000 @ $0.96 | EDGAR |
| 2022-03-17 | 4 | Oncocyte Corp (OCX) | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 · Grant/award (A): 375,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Oncocyte Corp (OCX) | Purchase (P): 50,000 @ $1.28 | EDGAR |
| 2022-01-13 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 40,000 (derivative) | EDGAR |
| 2021-08-05 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 25,000 (derivative) | EDGAR |
| 2021-07-02 | 4 | OncoCyte Corp (OCX) | Option exercise (M): 106,221 @ $0 · Tax withholding (F): 25,873 @ $0 · Option exercise (M): 106,221 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | OncoCyte Corp (OCX) | Option exercise (M): 65,000 @ $0 · Tax withholding (F): 15,834 @ $0 · Option exercise (M): 65,000 (derivative) @ $0 | EDGAR |
| 2021-03-22 | 4 | OncoCyte Corp (OCX) | Purchase (P): 11,000 @ $4.79 | EDGAR |
| 2021-03-12 | 4 | Oxford Immunotec Global PLC (OXFD) | Disposition to issuer (D): 4,081 @ $22 · Disposition to issuer (D): 7,457 (derivative) @ $13.35 · Disposition to issuer (D): 7,457 (derivative) @ $7.54 · Disposition to issuer (D): 7,457 (derivative) @ $7.51 · Disposition to issuer (D): 7,457 (derivative) @ $7.56 · Disposition to issuer (D): 14,914 (derivative) @ $9.50 · +2 more | EDGAR |
| 2021-03-04 | 4 | Precipio, Inc. (PRPO) | Grant/award (A): 2,069 (derivative) @ $0 · Grant/award (A): 5,171 (derivative) @ $0 | EDGAR |
| 2021-03-01 | 4 | OncoCyte Corp (OCX) | Grant/award (A): 500,000 (derivative) @ $5.34 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1299153 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs